文献速递前列腺癌

在磁共振引导活检时代使用基于血液的风险预测或前列腺特异性抗原进行重复前列腺癌筛查:STHLM3-MRI随机临床试验的二次分析

Repeat Prostate Cancer Screening using Blood-based Risk Prediction or Prostate-specific Antigen in the Era of Magnetic Resonance Imaging-guided Biopsies : A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
PubMed 文献 · Eur Urol Oncol · 2024-11-18

在STHLM3-MRI随机试验中,对初轮筛查未诊断前列腺癌且PSA≥1.5 ng/ml的男性,在2-3年后重复筛查时比较Stockholm3与PSA。Stockholm3检测Gleason≥7癌的AUC为0.765,PSA为0.651;Stockholm3≥0.15相比PSA≥3 ng/ml减少41%的MRI检查,但检出更少的Gleason≥7癌。作者认为Stockholm3用于重复筛查可减少MRI需求同时维持高危癌检出率。

要点

  • 重复筛查中Stockholm3检测Gleason≥7癌的AUC为0.765,PSA为0.651。
  • Stockholm3≥0.15相比PSA≥3 ng/ml减少41%的MRI检查(RPF 0.59)。
  • Stockholm3≥0.15检出更少Gleason≥7癌(RPF 0.75),GS≥4+3癌检出相似(RPF 1.00)。

核心结论

  • 使用Stockholm3进行重复前列腺癌筛查可减少MRI需求,同时维持高危癌的检出率。

研究设计与样本

  • 基于人群的STHLM3-MRI随机临床试验的二次分析,纳入初轮筛查未诊断前列腺癌且PSA≥1.5 ng/ml的男性,在2-3年后重复筛查时分析PSA和Stockholm3。
  • 初轮筛查7609名男性中,2078名符合重复筛查条件,1500名(72%)参与。
  • PSA≥3 ng/ml或Stockholm3≥0.11者行双参数1.5-T MRI,PI-RADS≥3者行靶向联合系统活检。

主要发现

  • 检测Gleason≥7前列腺癌的AUC:Stockholm3为0.765(95%CI 0.725-0.805),PSA为0.651(95%CI 0.601-0.701)。
  • Stockholm3≥0.15相比PSA≥3 ng/ml减少41%的MRI检查(RPF 0.59,95%CI 0.54-0.64)。
  • Stockholm3≥0.15检出更少Gleason≥7癌(RPF 0.75,95%CI 0.59-0.95)和Gleason 6癌(RPF 0.73,95%CI 0.46-1.16)。
  • GS≥4+3癌检出相似(RPF 1.00,95%CI 0.78-1.29)。
  • Stockholm3≥0.11与MRI检查数量无减少相关,但检出癌症病例数增加。

关键数值与推荐

  • Stockholm3≥0.15相比PSA≥3 ng/ml减少41%的MRI检查(RPF 0.59,95%CI 0.54-0.64)。
  • Stockholm3≥0.15检出Gleason≥7癌的RPF为0.75(95%CI 0.59-0.95)。
  • Stockholm3≥0.15检出Gleason 6癌的RPF为0.73(95%CI 0.46-1.16)。
  • GS≥4+3癌检出的RPF为1.00(95%CI 0.78-1.29)。

临床怎么用

  • 作者认为,使用Stockholm3进行重复前列腺癌筛查可减少MRI需求,同时维持高危癌的检出率。

局限性

  • 缺乏长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The use of blood-based risk prediction tools has been proposed to improve prostate cancer screening, but data on repeated screening are lacking. Our aim was to compare outcomes using the blood tests prostate-specific antigen (PSA) and Stockholm3 for repeat prostate cancer screening. METHODS: In the population-based screening-by-invitation STHLM3-MRI trial, men aged 50-74 yr were invited to participate in screening. At 2-3 yr after the initial round, men with PSA ≥1.5 ng/ml at trial inclusion who were randomized to magnetic resonance imaging (MRI)-enhanced screening and were not diagnosed with prostate cancer after the initial round were invited for repeat screening involving analysis of PSA and Stockholm3. Biparametric 1.5-T MRI was performed in cases with PSA ≥3 ng/ml or Stockholm3 ≥0.11. Men with Prostate Imaging0Reporting and Data System ≥3 lesions were referred for targeted plus systematic biopsies. The primary outcome was Gleason ≥7 cancer. Secondary outcomes included the number of MRI scans and biopsy procedures, and detection of Gleason 6 and Gleason ≥4 + 3 cancer. Outcomes were compared using the relative positive fractions (RPF). KEY FINDINGS AND LIMITATIONS: Of 7609 men from the initial screening round, 2078 were eligible for repeat screening and 1500 (72%) participated. For detection of Gleason ≥7 prostate cancer, the area under the receiver operating characteristic curve was 0.765 (95% confidence interval [CI] 0.725-0.805) for Stockholm3 and 0.651 (95% CI 0.601-0.701) for PSA. Stockholm3 ≥0.15 was associated with 41% fewer MRI scans in comparison to PSA ≥3 ng/ml (RPF 0.59, 95%CI 0.54-0.64), while the detection of GS ≥4 + 3 cancers was similar (RPF 1.00, 95% CI 0.78-1.29). Stockholm3 ≥0.15 detected fewer Gleason ≥7 (RPF 0.75, 95% CI 0.59-0.95) and Gleason 6 (RPF 0.73, 95% CI 0.46-1.16) cancers. Stockholm3 ≥0.11 was associated with no decrease in the number of MRI scans, but an increase of the number of cancer cases detected. Limitations include the lack of long-term outcomes. CONCLUSIONS AND CLINICAL IMPLICATIONS: Use of the Stockholm3 test for repeated prostate cancer screening could reduce the need for MRI while maintaining detection rates for high-risk cancer. PATIENT SUMMARY: In this study, we invited men to a second round of prostate cancer screening. We found that use of a new blood test called Stockholm3 can make screening programs more efficient by using fewer resources while still detecting aggressive cancers.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Discacciati A, Abbadi A, Clements MS, et al. Repeat Prostate Cancer Screening using Blood-based Risk Prediction or Prostate-specific Antigen in the Era of Magnetic Resonance Imaging-guided Biopsies : A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial. Eur Urol Oncol. 2024. PMID: 39562218. doi:10.1016/j.euo.2024.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。